Researcher

Chang Liu

Nankai University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 11, 2026 · JOURNAL ARTICLE

Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515)

Signal Transduction and Targeted Therapy

A multicenter retrospective real-world study with propensity weighting showing clinically meaningful improvements in response rates, PFS, and OS for a novel embolic agent versus standard care, but limited by retrospective design and real-world (non-randomized) conduct.

PromisingFengwei Gao Cholangiocarcinoma and Gallbladder Cancer Studies Xiaojuan Yang

Reported

Sample size328

ORR (RECIST 1.1) T-TACE54.11%

ORR (RECIST 1.1) D-TACE27.78%

AUG 10, 2026 · JOURNAL ARTICLE

Case Report: Successful trastuzumab deruxtecan rechallenge after disease progression in a pretreated HER2-mutated lung adenocarcinoma patient

Frontiers in Oncology

A single case report of T-DXd rechallenge in HER2-mutant lung cancer showing clinical benefit; interesting but cannot establish efficacy or safety generalizable to practice without prospective data.

PreliminaryY Hu Lung Cancer Treatments and Mutations Chang Liu

Reported

Progression-free survival on rech…14 months